Acadian Asset Management
ITCI

Acadian Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Acadian Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,056
Closed -$150K – 2259
2024
Q3 		$150K Buy
+2,056
New +$155K ﹤0.01% 1467
2018
Q1 		– Sell
-1,657
Closed -$24K – 1868
2017
Q4 		$24K Sell
1,657
-3,673
-69% -$56.7K ﹤0.01% 1345
2017
Q3 		$84K Buy
+5,330
New +$78.2K ﹤0.01% 1030
2017
Q2 		– Sell
-44,986
Closed -$731K – 1618
2017
Q1 		$731K Buy
+44,986
New +$651K ﹤0.01% 816

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Acadian Asset Management's ITCI Position: Q4 2024 in Review

Acadian Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 2,056 shares — an estimated $150K sold.

Acadian Asset Management first reported a position in ITCI in Q1 2017 and held it in 4 quarters. The position peaked at $731K in Q1 2017. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

  • Acadian Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 2,056 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $150K.
  • Acadian Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 4 quarters.
  • Acadian Asset Management's Intra-Cellular Therapies Inc. position peaked at $731K in Q1 2017.
  • 387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.